Visual Acuity Outcomes and Anti–Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes
[ad_1]
Recently co-authored: Real-world outcomes (~50,000 eyes) of anti-VEGF therapy for AMD – only 1 letter gained at 1 year, meaningfully worse than clinical trials. Download: https://lnkd.in/efPCAD5
https://www.sciencedirect.com/science/article/pii/S2468653019302805?via%3Dihub
This study assessed anti–vascular endothelial growth factor (VEGF) therapy intensity and its relationship with visual acuity (VA) change in real-world…
[ad_2]
Return to main website.